Danish biotech Genmab (Nasdaq: GMAB) posted second-quarter revenue of $925 million, up 19% from a year earlier, driven by higher royalties from Johnson & Johnson’s (NYSE: JNJ) Darzalex (daratumumab) ...

Drug-resistant infections now claim more lives each year than HIV/AIDS or malaria, and the toll is rising. The World Health Organization warns that without urgent action, antimicrobial resistance (AMR ...

Danish biotech Genmab (Nasdaq: GMAB) and US partner AbbVie (NYSE: ABBV) have reported a decisive win in a Phase III study of ...